CSPC INNOVATION PHARMACEUTICAL CO., LTD. · 新诺威
Last · Shenzhen¥43.63+0.50 (+1.16%)live · yahoo · 5h ago
Market cap¥61.3B1.40B sh
P/E · TTM59.8fwd 70.2 · eps 0.73
Beta-0.01vs S&P 500
Div yield0.00%annual · TTM
52w range
¥22.50¥51.78
Volume3.4Msession
| Revenue | ¥4.3B |
|---|---|
| Operating income | ¥1.6B |
| Net income | ¥1.3B |
| Free cash flow | ¥2.5B |
| Operating margin | 36.1% |
| Net margin | 29.0% |
| Return on equity | 32.0% |
| Period | TTM 2026-06-30 |
Loading chart…
Documents
FormReporting forFiledFlags
slidesPHASE III CLINICAL STUDY RESULTS OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER SELECTED FOR LBA ORAL PRESENTATION AT THE 2026 ASCO ANNUAL MEETINGIR
—2026-12-31≈0